Laboratory developed tests vs FDA cleared assays: two paths

Laboratory Developed Tests vs FDA-Cleared Assays: Two Paths

It is an operating model with different compliance obligations, staffing requirements, capital exposure, and failure modes.

The 2025 federal court vacatur of the FDA’s laboratory developed test rule removed one layer of uncertainty, but it did not eliminate the management problem. LDTs remain primarily governed as clinical laboratory services under CLIA. Commercial assays continue to arrive with a manufacturer-defined intended use, established documentation, and a regulatory file that the laboratory can leverage. Neither path is automatically safer, cheaper, or more defensible.

The correct decision depends on the laboratory’s menu strategy, specimen volume, turnaround-time requirements, validation capacity, reimbursement environment, and tolerance for operational complexity.

The regulatory reset after the 2025 vacatur

The FDA published its LDT Final Rule on May 6, 2024. The rule attempted to bring LDTs under the agency’s medical-device framework and phase out the previous general enforcement-discretion approach. That would have materially changed the economics of in-house testing. Laboratories would have faced a broader device-oriented compliance burden in addition to their existing CLIA obligations.

On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the rule in its entirety. The court held that the FDA lacked statutory authority under the Federal Food, Drug, and Cosmetic Act to regulate professional LDT services as medical devices. In September 2025, the FDA formally rescinded the rule.

The practical result is straightforward:

• LDTs remain primarily regulated as laboratory services under CLIA.
• The FDA’s 2024 LDT rule is not currently in effect.
• A CLIA certificate does not grant FDA premarket clearance or approval for diagnostic kits distributed to other laboratories.
• A laboratory that modifies an FDA-cleared or De Novo-authorized assay is generally dealing with a new LDT for CLIA validation purposes.
• State requirements continue to operate independently of the federal FDA device framework.

This is a regulatory reset, not a compliance holiday. CLIA still requires the laboratory to establish that a test performs as claimed before reporting patient results. The laboratory must control the entire process: specimen acceptance, analytic procedure, quality control, result interpretation, reporting, personnel competency, corrective action, and documentation.

The court vacatur changed the federal regulatory perimeter. It did not lower the operational standard for producing a defensible patient result.

The distinction matters because laboratories often confuse the absence of FDA premarket review with the absence of premarket responsibility. An LDT can avoid the FDA device pathway while still requiring a substantial internal validation program. The risk does not disappear. It moves into the laboratory’s quality system, personnel model, documentation, and accreditation exposure.

What the two pathways actually require

An FDA-cleared or FDA-approved in vitro diagnostic is manufactured and distributed for clinical use according to a defined intended use. Depending on the product, the manufacturer may have obtained 510(k) clearance, De Novo authorization, PMA approval, or another applicable authorization. The purchasing laboratory is not starting with a blank page. It receives manufacturer instructions, performance claims, quality-control recommendations, labeling, and implementation documentation.

That does not mean the laboratory can install the kit and immediately report results. The laboratory still has to verify performance under its own operating conditions. Instruments, operators, specimen types, software interfaces, local prevalence, and workflow design can affect real-world performance. Verification is usually narrower than building a complete validation package for an entirely new method, but it is still a laboratory responsibility.

An LDT is designed, manufactured, and used within a single CLIA-certified laboratory entity. The laboratory owns the method. It owns the intended-use language. It owns the validation record. It owns the response when the assay fails, drifts, produces an unexpected result, or becomes difficult to reproduce after a reagent or instrument change.

The operating comparison is best understood this way:

The comparison is not a contest between innovation and bureaucracy. It is a decision about where the burden sits. With an LDT, more burden sits inside the laboratory. With a commercial assay, more burden sits with the manufacturer, but the laboratory accepts greater dependence on the vendor’s design and supply chain.

CLIA compliance is the operating system for an LDT

For laboratory directors, the central question is not whether an LDT is legally available. The question is whether the laboratory can sustain the method under routine production conditions.

Clinical validation of laboratory developed tests must be treated as an operating program, not a one-time document assembled for inspection. The validation package should reflect the actual intended use and the level of risk attached to the result. A narrowly defined qualitative assay and a broad quantitative assay do not carry the same evidence burden. A test used for a high-consequence treatment decision demands stronger controls than a low-impact screening application.

The laboratory’s documentation should establish, at a minimum, how it evaluated the following areas where applicable:

• Accuracy or agreement against an appropriate comparator.
• Precision and reproducibility across operators, runs, instruments, days, and relevant concentrations.
• Analytical sensitivity, including the lower end of reportable performance where that affects clinical interpretation.
• Analytical specificity and interference risk.
• Reportable range and linearity for quantitative methods.
• Carryover, contamination control, and invalid-result handling.
• Specimen stability, storage, transport, and rejection criteria.
• Reference intervals or decision thresholds when the assay produces quantitative or interpretive results.
• Result interpretation, report wording, limitations, and reflex testing.
• Quality-control frequency, acceptance criteria, and escalation procedures.

The exact design must follow the assay and its intended use. The point is managerial: every performance claim creates a maintenance obligation. If a laboratory claims the method works with several specimen types, instruments, or clinical populations, it must control and support those claims.

An LDT also creates a larger change-control surface. Reagent lots change. Extraction platforms are replaced. software versions are updated. A supplier may discontinue a critical component. The laboratory may alter primer or probe concentrations, introduce a new specimen matrix, revise a cutoff, or connect the result to a different LIS workflow. Each change must be assessed for impact.

A mature change-control process answers five direct questions:

1. What changed?

2. Which analytical or clinical claims could be affected?

3. What evidence is required before implementation?

4. Who approves the change?

5. How will the laboratory detect deterioration after go-live?

The fifth question is frequently neglected. Validation proves readiness at a defined point in time. Quality monitoring demonstrates continued control. Proficiency testing, alternative assessment, internal quality-control trends, lot-to-lot review, amended reports, complaint review, and clinician feedback all contribute to that control system.

Personnel capacity is a financial variable

The laboratory may have the instrumentation to run an LDT and still lack the personnel capacity to operate it responsibly. Method development, validation, troubleshooting, competency assessment, quality review, and regulatory documentation consume senior scientific and supervisory time. Those hours belong in the cost model.

A test that appears inexpensive at the reagent level can carry substantial labor overhead. The margin calculation should account for:

• Development and validation labor.
• Medical director and technical supervisor review.
• Quality-management administration.
• Competency assessment and retraining.
• Reagent qualification and supply-chain monitoring.
• Instrument downtime and backup procedures.
• Result review and exception handling.
• Informatics build, interface maintenance, and report updates.
• Proficiency testing or alternative assessment.
• Corrective and preventive action activity.

Commercial assays do not remove these costs. They can reduce internal method-development burden, but they introduce other costs: proprietary consumables, instrument contracts, service fees, minimum purchase commitments, vendor-mandated workflows, and exposure to allocation or discontinuation.

The relevant metric is not reagent price. It is total cost per reportable result at the laboratory’s actual throughput.

Analytical performance: commercial status is not a substitute for evidence

The argument that commercial assays are inherently analytically superior is not supported by the available proficiency-testing evidence. A College of American Pathologists molecular oncology proficiency-testing analysis covering BRAF, EGFR, and KRAS testing found comparable high analytical performance across thousands of proficiency-testing responses for LDTs and FDA-approved companion diagnostics.

That finding should be used correctly. It does not mean every LDT performs well. It does not mean every commercial kit performs well in every laboratory. It means regulatory category alone is a poor proxy for routine analytical performance.

Performance depends on method design, specimen handling, contamination control, operator competency, instrument maintenance, quality-control discipline, and result interpretation. A weak laboratory can implement a commercial assay badly. A strong laboratory can build and sustain an LDT with high performance.

The operational question is therefore not, “Which label is safer?” It is, “Which organization can control the full testing process with fewer failure points?”

A useful risk-based approach to diagnostic test validation should examine the actual clinical and operational consequences of error:

• What happens if the assay produces a false negative?
• What happens if an indeterminate result delays treatment?
• How quickly can the laboratory investigate a quality event?
• Is there a second method or referral laboratory available?
• Can the laboratory maintain testing during a reagent shortage?
• How much of the result depends on software, algorithmic interpretation, or manual review?
• Does the laboratory have enough volume to detect performance drift?
• Can the laboratory defend its claims to an accreditor, payer, hospital committee, or regulator?

High-volume standardized tests may favor a commercial platform because the laboratory gains implementation speed, vendor support, and a predictable operating procedure. Highly specialized tests may favor an LDT because the commercial market does not offer the required targets, specimen types, turnaround time, or reporting model.

The answer must be based on evidence and throughput. A test with low volume but high clinical value may justify an LDT if its contribution margin supports the fixed validation and quality burden. A test with steady volume but narrow margins may be better purchased if the commercial platform reduces labor and downtime enough to protect capacity.

The strategic trade-off: flexibility against control burden

Laboratory directors should treat the choice as a portfolio decision. Not every assay on the menu should follow the same path.

When an LDT can be the stronger operating choice

An LDT may be justified when the laboratory needs a capability that commercial products do not provide. Common drivers include:

• A novel biomarker or emerging clinical application.
• A specialized specimen type not covered by the commercial product’s intended use.
• A locally required turnaround time.
• A need to combine targets, controls, or reflex rules in a custom workflow.
• A patient population or disease pattern that requires a tailored design.
• A business strategy built around differentiated testing rather than commodity volume.
• A need to avoid dependence on a single manufacturer’s product roadmap.

The advantage is control. The laboratory can optimize the workflow, design the reporting logic, and adapt the assay to the service line. The price is accountability. Every element becomes an internal process that must be validated, documented, monitored, and defended.

An LDT is particularly vulnerable to hidden fixed costs. A laboratory may focus on consumables while ignoring the time required to maintain the method. If the test volume is low, the per-result cost can become uncompetitive. If the assay is highly complex, the laboratory may also face concentration risk around one technical supervisor or one supplier.

When a commercial assay is the stronger operating choice

An FDA-cleared, approved, or otherwise authorized assay may be preferable when the laboratory needs standardized implementation, predictable deployment across multiple sites, or a rapid expansion of routine capacity.

Commercial products can reduce the internal burden of assay design and provide a common framework for training, quality documentation, troubleshooting, and cross-site harmonization. They may also simplify conversations with hospital leadership and clinicians who want a recognized product with defined labeling.

The disadvantages are equally practical:

• The laboratory may be locked into a vendor’s consumable pricing.
• A product may be unavailable during allocation or supply disruption.
• The manufacturer may discontinue the assay or instrument.
• The intended use may not match the laboratory’s desired specimen type or workflow.
• Proprietary software can limit visibility into result generation.
• Per-test economics may deteriorate as reimbursement changes.
• A commercial platform may create excess capacity if volume assumptions are wrong.

A commercial assay is not automatically a lower-risk investment. It can create a different risk profile: vendor concentration, contract exposure, instrument dependency, and limited flexibility. Procurement must evaluate the complete supply chain rather than the first-year reagent quote.

The cheapest assay on the purchase order is not necessarily the lowest-cost test in production. Throughput, downtime, validation labor, and supply continuity determine margin.

A practical decision framework

Before approving a new LDT or commercial platform, the laboratory should force the business case through a common framework:

1. Define the clinical use. Specify the patient population, specimen types, decision thresholds, turnaround time, and reporting requirements.

2. Map the compliance burden. Identify CLIA validation or verification work, accreditation expectations, state requirements, proficiency testing, and change-control obligations.

3. Model full operating cost. Include labor, equipment, service, consumables, informatics, quality management, downtime, and referral costs.

4. Test the volume assumption. Calculate expected reportable results, not theoretical instrument capacity.

5. Stress the supply chain. Identify second sources, critical components, manufacturer commitments, and realistic recovery options.

6. Assess clinical failure impact. Rank errors by potential effect on treatment, reporting, patient delay, and institutional risk.

7. Set an exit plan. Define what would trigger migration, suspension, referral, or retirement of the method.

This framework also improves governance. A laboratory should not approve an LDT because a scientist can build it, or purchase a commercial system because a vendor has a compelling implementation presentation. The method must earn its place in the menu through clinical utility, operational capacity, compliance readiness, and sustainable economics.

State oversight remains a separate exposure

Federal status does not settle every question. New York provides the clearest example of why laboratories must maintain a state-by-state compliance map.

New York State requires laboratories performing non-FDA-cleared diagnostic tests for New York patients to obtain test-specific approval through the New York State Clinical Laboratory Evaluation Program, or CLEP. That requirement operates independently of the federal FDA device framework.

The 2025 federal court decision did not remove this state-level obligation. A laboratory may be operating an LDT under CLIA and still need separate approval before testing New York patients. This affects menu design, routing logic, contracting, and the operational feasibility of centralized testing models.

A laboratory serving multiple states should maintain a matrix that tracks, for each assay and patient location:

• Whether the method is an LDT or a commercial FDA-authorized product.
• Which state approvals or registrations apply.
• Whether the specimen may be tested at the intended site.
• Whether reporting language must change by jurisdiction.
• Whether the state imposes additional validation, personnel, or quality requirements.
• Whether a change to the method requires a new state submission or review.

State compliance cannot be left to specimen accession staff. The LIS and ordering workflow should support jurisdictional controls where feasible. If a test cannot legally be performed for a particular patient location, the system should prevent the laboratory from discovering that fact after the specimen has entered production.

New York is not merely an exception to memorize. It is an operating warning. Federal classification and state authorization are separate dimensions of laboratory risk.

The post-2025 strategy for laboratory leaders

The current environment favors laboratories that can separate regulatory facts from operational assumptions.

LDTs remain available under the post-vacatur framework, but they require disciplined CLIA execution. Commercial assays remain useful because they reduce certain development and standardization burdens, but they do not eliminate verification, quality management, or supply-chain risk. FDA authorization is valuable evidence. It is not a substitute for local implementation control.

The strongest laboratories will manage both pathways deliberately:

• Use LDTs where differentiation, clinical need, or workflow flexibility creates measurable value.
• Use commercial assays where standardization, deployment speed, and vendor support improve total economics.
• Avoid maintaining multiple methods without a clear clinical or financial rationale.
• Treat validation records as living quality assets rather than inspection paperwork.
• Track reportable throughput, invalid rates, turnaround time, reagent loss, downtime, and labor hours by method.
• Build state-specific compliance into the test menu and LIS governance.
• Review vendor concentration and contingency capacity before a supply disruption exposes the weakness.

The strategic mistake is not choosing the wrong category in the abstract. It is failing to calculate the operating consequences of the chosen category.

Laboratory developed tests vs FDA-cleared assays is ultimately a question of control. The LDT gives the laboratory more control over the method and more responsibility for the result. The commercial assay gives the laboratory more external structure and more dependence on the manufacturer. Both can support high-quality molecular diagnostics. Neither protects an organization that cannot maintain throughput, documentation, personnel competency, and compliance discipline.

The regulatory landscape is more stable after the 2025 vacatur, but the management standard is unchanged: every reported result must be supported by a controlled process, defensible evidence, and an operating model that can survive the next reagent change, inspection, staffing shortage, and reimbursement cycle.